The US could upend biopharma manufacturing. WuXi rivals have an opening

In Con­gress, in­flu­en­tial law­mak­ers see a Chi­nese gov­ern­ment threat to the US biotech sec­tor. In the com­pet­i­tive world of bio­phar­ma man­u­fac­tur­ing, com­pa­nies see an op­por­tu­ni­ty.

Over the past sev­er­al months, as WuXi AppTec, WuXi Bi­o­log­ics and BGI Group have been tar­get­ed by law­mak­ers with pro­posed leg­is­la­tion and sanc­tions, their ri­vals have qui­et­ly — and not so qui­et­ly — used the mo­ment to try and gain mar­ket share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.